Parkinson’s Disease

What Is Parkinson’s Disease?

Parkinson’s disease is a progressive neurodegenerative condition caused by the loss of dopamine producing neurons within a specific midbrain structure called the substantia nigra.¹

The disease’s defining pathological feature involves the accumulation of abnormal protein clusters called Lewy bodies within surviving neurons, composed primarily of a protein called alpha synuclein, whose abnormal buildup appears to perpetuate ongoing neuronal damage.²

Notably, motor symptoms only become clinically apparent after a substantial proportion of dopamine producing neurons, estimated at seventy to eighty percent, have already been lost, meaning significant underlying disease progression occurs before diagnosis typically happens.¹

Parkinson’s disease is characterized by the loss of dopaminergic neuronal cells in the substantia nigra pars compacta and the abnormal accumulation and aggregation of alpha synuclein in the form of Lewy bodies and Lewy neurites.
National Center for Biotechnology Information

Symptoms

The classic motor symptoms of Parkinson’s disease include bradykinesia, or slowness of movement, resting tremor, muscular rigidity, and postural instability, all resulting directly from dopamine deficiency within a brain region called the striatum.¹

Beyond these well recognized motor symptoms, Parkinson’s disease frequently produces a range of non-motor symptoms, including reduced sense of smell, constipation, depression, and pain, which can sometimes precede motor symptoms by years.²

In later disease stages, cognitive decline and dysautonomia, meaning dysfunction of the body’s automatic regulatory systems, can develop, adding meaningful additional complexity to disease management as it progresses.²

Causes

Parkinson’s disease results from progressive loss of dopamine producing neurons within the substantia nigra, directly reducing dopamine availability within brain circuits responsible for coordinating smooth, controlled movement.¹

Alpha synuclein protein accumulation plays a central role in this neurodegenerative process, and mutations affecting the gene responsible for producing this protein represented the first genetic cause of Parkinson’s disease ever identified.²

The disease’s underlying cause reflects a complex combination of genetic and environmental risk factors, with only a relatively small proportion of cases directly attributable to known, identifiable genetic mutations.³

Risk Factors

Advancing age and male sex both represent the most consistently identified risk factors for Parkinson’s disease, with risk rising substantially as people grow older.³

Environmental exposures, including pesticide exposure, prior head injury, and living or working in farming and rural agricultural environments, have all been associated with increased Parkinson’s disease risk.³

Specific genetic mutations, including those affecting genes called Parkin and glucocerebrosidase, contribute to a meaningful subset of cases and appear to influence not just disease risk but also disease onset age and long term progression pattern.⁴

Complications

As Parkinson’s disease progresses, worsening motor symptoms increasingly interfere with daily activities, balance, and overall mobility, contributing to significant functional decline over time.

Cognitive impairment and psychiatric symptoms represent important disease related complications, and their presence carries meaningful implications for treatment planning, including candidacy for certain surgical interventions.⁵

Interestingly, specific genetic mutation status appears to influence complication risk following certain treatments, with carriers of glucocerebrosidase mutations shown to develop cognitive impairment earlier following surgical treatment compared to patients with other genetic profiles.⁴

Treatment

Levodopa remains the gold standard medication for Parkinson’s disease, working by replenishing dopamine levels within the brain and providing meaningful improvement in motor symptoms for most patients.¹

Deep brain stimulation represents an important surgical treatment option, involving implantation of a device that delivers targeted electrical stimulation to specific brain regions, shown to improve motor function and often allowing a significant reduction in medication dosage.⁵

Treatment outcomes following deep brain stimulation depend on several individual factors, including disease duration, age at disease onset, how well symptoms respond to levodopa, and the presence of any cognitive or psychiatric conditions, underscoring the importance of careful, individualized patient selection.⁵

Prevention

Because Parkinson’s disease results from a complex combination of genetic and environmental factors, there is no established way to reliably prevent the condition from developing.

Limiting occupational and environmental exposure to pesticides, where possible, may help reduce individual risk given the documented association between this exposure and increased disease risk.³

For people with known genetic risk factors, understanding how specific mutations may influence disease course and treatment response supports more informed, personalized long term care planning.⁴

Why Visual Communication Matters for Parkinson’s Disease

Explaining how the loss of a relatively small, specific population of brain cells can produce such profound effects on movement requires visuals that make this precise neuroanatomical relationship clear and memorable.

Pharmaceutical companies, neurology practices, and patient education organizations rely on clear illustration and animation to explain Parkinson’s disease biology and support informed treatment decisions.

• Illustrating dopamine neuron loss within the substantia nigra
• Animating alpha synuclein accumulation and Lewy body formation
• Explaining the mechanism of action of levodopa and deep brain stimulation
• Visualizing how genetic mutation status influences disease course and treatment
• Supporting patient education on motor and non-motor symptom management
• Creating training materials for neurology and neurosurgery clinicians

How Biotic Artlab Supports Parkinson’s Disease Communication

We work with pharmaceutical companies, neurology practices, and patient advocacy organizations to create scientifically accurate visuals that make Parkinson’s disease and its treatment easier to understand.

• Custom 3D animations of dopamine neuron loss and Lewy body pathology
• Detailed illustrations of deep brain stimulation device placement and function
• Mechanism of action animations for levodopa and other Parkinson’s medications
• Patient facing materials on motor and non-motor symptom recognition
• Clinical training content for neurology and neurosurgery teams
• Conference presentations and marketing visuals for movement disorder audiences

Frequently Asked Questions

What causes Parkinson’s disease?

The condition results from loss of dopamine producing neurons in the substantia nigra, driven by abnormal accumulation of a protein called alpha synuclein.¹

What are the classic symptoms of Parkinson’s disease?

Slowness of movement, resting tremor, muscular rigidity, and postural instability represent the classic motor symptoms, often accompanied by non-motor symptoms such as reduced smell and depression.¹

How much dopamine loss occurs before symptoms appear?

Motor symptoms typically emerge only after seventy to eighty percent of dopamine producing neurons have already been lost.¹

What is the main medication treatment for Parkinson’s disease?

Levodopa remains the gold standard treatment, working by replenishing dopamine levels within the brain.¹

What is deep brain stimulation?

It is a surgical treatment involving an implanted device that delivers targeted electrical stimulation, improving motor symptoms and often reducing medication needs.⁵

Are there known risk factors for Parkinson’s disease?

Yes, advancing age, male sex, pesticide exposure, head injury, and certain genetic mutations have all been associated with increased risk.³

Have a Project in Mind? Contact Us.

If you are developing patient education materials, clinical training content, or marketing visuals related to Parkinson’s disease or movement disorders, our team can help translate the science into visuals that are both accurate and easy to understand. Contact us at info@biotic-artlab.com or get in touch through our contact form to discuss your project.

References

1. National Center for Biotechnology Information. Parkinson Disease.
2. National Center for Biotechnology Information. Alpha-Synuclein in Parkinson’s Disease, From Pathogenetic Dysfunction to Potential Clinical Application.
3. National Center for Biotechnology Information. An Update on the Diagnosis and Treatment of Parkinson Disease.
4. National Center for Biotechnology Information. Deep Brain Stimulation in Patients With Mutations in Parkinson’s Disease Related Genes, a Systematic Review.
5. National Center for Biotechnology Information. An Update on Best Practice of Deep Brain Stimulation in Parkinson’s Disease.

Disclaimer: This page provides general educational information and is not a substitute for diagnosis, treatment, emergency care, or individualized advice from a qualified healthcare professional.